chr11-108272729-C-G
Position:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_000051.4(ATM):c.3161C>G(p.Pro1054Arg) variant causes a missense change. The variant allele was found at a frequency of 0.022 in 1,613,692 control chromosomes in the GnomAD database, including 492 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.017 ( 30 hom., cov: 32)
Exomes 𝑓: 0.023 ( 462 hom. )
Consequence
ATM
NM_000051.4 missense
NM_000051.4 missense
Scores
6
6
6
Clinical Significance
Conservation
PhyloP100: 6.36
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0074827075).
BP6
Variant 11-108272729-C-G is Benign according to our data. Variant chr11-108272729-C-G is described in ClinVar as [Likely_benign]. Clinvar id is 132695.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-108272729-C-G is described in Lovd as [Benign]. Variant chr11-108272729-C-G is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.0165 (2517/152258) while in subpopulation NFE AF= 0.0269 (1829/68022). AF 95% confidence interval is 0.0259. There are 30 homozygotes in gnomad4. There are 1134 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 30 AD,AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.3161C>G | p.Pro1054Arg | missense_variant | 22/63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATM | ENST00000675843.1 | c.3161C>G | p.Pro1054Arg | missense_variant | 22/63 | NM_000051.4 | ENSP00000501606.1 |
Frequencies
GnomAD3 genomes AF: 0.0166 AC: 2521AN: 152140Hom.: 30 Cov.: 32
GnomAD3 genomes
AF:
AC:
2521
AN:
152140
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0166 AC: 4160AN: 251228Hom.: 61 AF XY: 0.0169 AC XY: 2302AN XY: 135822
GnomAD3 exomes
AF:
AC:
4160
AN:
251228
Hom.:
AF XY:
AC XY:
2302
AN XY:
135822
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0226 AC: 33044AN: 1461434Hom.: 462 Cov.: 32 AF XY: 0.0224 AC XY: 16284AN XY: 727028
GnomAD4 exome
AF:
AC:
33044
AN:
1461434
Hom.:
Cov.:
32
AF XY:
AC XY:
16284
AN XY:
727028
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0165 AC: 2517AN: 152258Hom.: 30 Cov.: 32 AF XY: 0.0152 AC XY: 1134AN XY: 74440
GnomAD4 genome
AF:
AC:
2517
AN:
152258
Hom.:
Cov.:
32
AF XY:
AC XY:
1134
AN XY:
74440
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
106
ALSPAC
AF:
AC:
127
ESP6500AA
AF:
AC:
26
ESP6500EA
AF:
AC:
196
ExAC
AF:
AC:
2046
Asia WGS
AF:
AC:
22
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:19Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Ataxia-telangiectasia syndrome Benign:5
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 01, 2021 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | Counsyl | Jan 19, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Benign, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Hereditary cancer-predisposing syndrome Benign:4
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 18, 2014 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, no assertion criteria provided | clinical testing | True Health Diagnostics | Jan 25, 2018 | - - |
Benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 10, 2014 | - - |
Benign, criteria provided, single submitter | curation | Sema4, Sema4 | May 10, 2020 | - - |
not specified Benign:3Other:1
Benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Feb 09, 2015 | - - |
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2015 | This variant is associated with the following publications: (PMID: 30957677, 31382929, 26122175, 18502988, 24728327, 27599564, 27153395, 10464642, 17502119, 22529920, 21833744, 19431188, 23585524, 15101044, 11996792, 20826828, 23125224) - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 17, 2023 | - - |
Familial cancer of breast Benign:2
Benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | May 13, 2024 | This variant is considered benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. - |
Benign, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jul 07, 2023 | - - |
Carcinoma of colon Benign:1
Benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The ATM p.Pro1054Arg variant was identified in both proband chromosomes (frequency not specified) from Swiss, Brazilian and European individuals or families with (early onset or sporadic) breast cancers, and in control chromosomes (frequency not specified) from healthy individuals (Mangone 2015, Milne 2009, Maillet 2002), increasing the likelihood this variant is not associated with breast cancer. Genotyping of 5 polymorphisms (with MAF 0.9-2.6%) including this variant in a large case control study, showed that the 5 missense polymorphisms were associated with a small increased risk of breast cancer (Fletecher 2010). The variant was confirmed to be associated with an increased risk of prostate cancer in a cohort of prostate cancer cases, being identified in 50 of 522 proband chromosomes (frequency 0.096), and 22 of 920 healthy controls were found to be carriers (1 homozygous, frequency: 0.024, Meyer 2007). The variant was identified in dbSNP (ID: rs1800057) as “With Benign allele”, Clinvitae database (classified as benign), ClinVar database (classification benign by Ambry Genetics, Emory Genetics, Color Genomics Inc, Prevention Genetics, Invitae and not classified by ITMI), and in COSMIC (in a squamous cell carcinoma, and lymphoid neoplasm-Burkitt lymphoma). The variant was also identified in LOVD 3.0 (2x) databases, but not in the ATM-LOVD database. The variant was identified in control databases in 4511 of 277018 chromosomes at a frequency of 0.016284 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Consortium Feb 27, 2017). The variant was identified in the following populations at a frequency greater than 1%: European (Non-Finnish) in 3306 of 126596 chromosomes (freq: 0.026), Ashkenazi Jewish in 224 of 10148 chromosomes (freq: 0.022), Other in 122 of 6458 chromosomes (freq: 0.019), Latino in 390 of 34412 chromosomes (freq: 0.011). The p.Pro1054 residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs 8 nucleotides from the intron-exon junction and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information, this variant meets our laboratory's criteria to be classified as benign. - |
Hereditary breast ovarian cancer syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | National Health Laboratory Service, Universitas Academic Hospital and University of the Free State | Apr 19, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
.;D;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
D;D;.
MetaRNN
Benign
T;T;T
MetaSVM
Uncertain
T
MutationAssessor
Uncertain
.;M;M
PrimateAI
Benign
T
PROVEAN
Pathogenic
D;D;D
REVEL
Uncertain
Sift
Pathogenic
D;D;D
Sift4G
Pathogenic
D;D;D
Polyphen
1.0
.;D;D
Vest4
0.95, 0.92
MPC
0.59
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at